RxDoctor Payments DataLook up a doctor →

Ghulam Kashef, MD

Medical Oncology · Henderson, NVNPI 1679662688

Payments from drug & device makers

$10,603in general payments, 2019–2025

Across 555 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$2K
  • Novartis$689
  • AstraZeneca$628
  • Regeneron Healthcare Solutions, Inc.$477
  • Merck$400
  • Genentech USA, Inc.$396
  • plus $6K from 47 others

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Daiichi Sankyo Inc.136$1,691
Novartis39$689
AstraZeneca30$628
Regeneron Healthcare Solutions, Inc.22$477
Merck17$400
Genentech USA, Inc.18$396
Amgen17$394
Pfizer23$385
Sobi, Inc36$364
Bristol Myers Squibb16$353
Exelixis Inc.14$347
Johnson & Johnson13$298
AbbVie14$296
Astellas Pharma US Inc12$277
Gilead11$265
Seagen Inc.4$236
Karyopharm Therapeutics Inc.7$235
GSK10$224
Beigene USA, Inc.7$193
Sanofi6$182
Tempus AI, Inc8$169
Takeda Pharmaceuticals U.S.A., Inc.7$165
Incyte Corporation6$146
Mirati Therapeutics, Inc.7$137
EMD Serono, Inc.6$119
Boehringer Ingelheim4$115
Beone Medicines USA, Inc.4$113
Stemline Therapeutics Inc.6$108
Eisai Inc.5$104
Array Biopharma Inc7$95
Sanofi-aventis U.S. LLC1$89
Lilly USA, LLC5$85
Sumitomo Pharma America, Inc.4$84
Bayer3$68
E.r. Squibb & Sons, L.L.C.3$62
Genmab U.S., Inc.3$54
Rigel Pharmaceuticals, Inc.2$50
Pharmacyclics LLC, An Abbvie Company2$46
Coherus Oncology, Inc.2$46
Taiho Oncology, Inc.2$44
Geron Corporation2$39
Puma Biotechnology, Inc.2$38
Novocure Inc.2$37
Telix Pharmaceuticals1$36
Dendreon Pharmaceuticals LLC1$35
Alnylam Pharmaceuticals Inc.1$27
Azurity Pharmaceuticals, Inc.1$25
Ipsen Biopharmaceuticals, Inc1$25
Avyxa Pharma, LLC1$24
Sun Pharmaceutical Industries Inc.1$24
Myovant Sciences Inc.1$24
Jazz Pharmaceuticals Inc.1$20
Sirtex Medical Inc1$18

How this compares

Too few medical oncology providers in Nevadato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$5,672,095
Medicare patients
856
Services billed
233,008

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Henderson

See the full list for Nevada →

Where these figures come from

Is this you, or does something look wrong? →